Contrave, A New Weight Loss Pill Combines Anti-Addiction Medication And An Antidepressant

Contrave, A New Weight Loss Pill Combines Anti-Addiction Medication And An Antidepressant.
An trained admonition panel recommended on Tuesday that Contrave, a inexperienced weight-loss pill that combines an antidepressant with an anti-addiction medication, be approved by the US Food and Drug Administration. The 13-7 plebiscite in favor of Contrave came amid agency concerns that the benumb might raise blood pressure in some patients and increase the risk of heart attacks and strokes amongst some users, according to the Associated Press review. But panelists voted 11-8 earlier in the epoch that those potential health risks could be studied after Contrave was approved.

The FDA does not have to follow the advice of its advisory committees, but it typically does. The means is expected to make a decision on Contrave by Jan 31, 2011, the wire assignment reported. contrave is manufactured by orexigen therapeutics inc. In October, the FDA voted against approving two other weight-loss drugs, Arena Pharmaceuticals' lorcaserin and Vivus' Qnexa, because of safeness concerns, according to the AP anti aging acne moisturizer. Last July, a workroom funded by Orexigen and published in The Lancet found that Contrave helped users hutch pounds when taken along with a wholesome diet and exercise.

People who took the drug for more than a year lost an average of 5 percent or more of body weight, depending on the administer used, the team said. However, the regimen did come with side effects, and about half of lucubrate participants dropped out before completing a year of treatment. Contrave is combination of two noted drugs, naltrexone (Revia, used to fight addictions) and the antidepressant bupropion (known by a many of names, including Wellbutrin).

The drug appears to boost weight loss by changing the workings of the body's medial nervous system, the researchers said. The study enrolled men (15 percent) and women (85 percent) from around the country, ranging in long time from 18 to 65. They were all either paunchy or overweightm, with high blood fat levels or high blood pressure.

The participants were told to snack less and exercise, and they were randomly assigned to take a twice-daily placebo or a union of the two drugs at one of two levels. After 56 weeks, only about half (870) of the more than 1700 participants initially enrolled remained in the study. Almost half (48 percent) of those who took the highest measure of naltrexone perplexed 5 percent of their weight or more, while only 16 percent of those who took placebos did.

However, about 30 percent of those taking Contrave skilled nausea, the study authors say, and other lesser effects included headache, constipation, dizziness, vomiting and dry mouth. Still, Contrave may give forebears struggling to lose weight a new option, the researchers contended.

The Lancet findings repeat those of studies into other diet drugs such as Meridia, Xenical and Alli, said Lona Sandon, an deputy professor of clinical nutrition at the University of Texas Southwestern Medical Center in Dallas and spokeswoman for the American Dietetic Association. "When these are combined with a modestly reduced calorie diet, unobtrusive amounts of heft loss are achieved. One striking thingumabob to note is the study drop-out rate of 50 percent. This may have been due to side effects of medications, the episode that it is hard to stick to dietary changes for 56 weeks, or the fact that slow and only modest mass loss did not meet participant expectations".

Cynthia Sass, a New York City-based nutritionist and author, added that drugs old to treat addiction also appear to help with weight control, supporting "the crotchet that food can be addictive for many people". An accompanying Lancet editorial noted that one solicitude is that blood pressure did not drop as much as expected in the higher weight-loss group our website. "More data are needed to get a better overall assessment of cardiovascular jeopardize of this otherwise promising combination therapy for obesity," wrote Professor Arne Astrup, a nutrition proficient at the University of Copenhagen, Denmark.